Hejing Biotech (688068.SH) released semi-annual results, with a net loss of 126 million yuan

According to Zhitong Finance App News, Hotview Biotech (688068.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved operating income of 268 million yuan, an increase of 31.60%; net profit loss attributable to shareholders of listed companies was 126 million yuan, an increase over the previous year; net profit loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 144 million yuan, an increase over the previous year; and basic earnings per share - 1.36 yuan.

The company's revenue for the first half of 2026 increased by 31.60% compared with the same period last year, mainly due to the continuous increase in revenue from the company's C-series large light emitting platform products and the large increase in revenue from the company's newly developed biotechnology consumer goods.

In the first half of 2026, the company's net profit attributable to shareholders of listed companies and net profit loss attributable to shareholders of listed companies increased year-on-year losses, leading to a significant year-on-year decline in indicators such as basic earnings per share, diluted earnings per share, basic earnings per share after deducting non-recurring profit and loss, weighted average return on net assets, and weighted average return on net assets after deducting non-recurring profit and loss. At the same time, the net cash flow from the company's operating activities was 11,1729,500 yuan, an increase of 97.9266 million yuan over the previous year's year-on-year outflow. This is mainly due to the sharp year-on-year increase in early research and clinical investment of the company's subsidiary Shunjing Pharmaceutical during the reporting period.